Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The burden of inflammatory bowel disease in Europe in 2020

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A reliability study - strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. ECCO topical review: Refractory Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10-30% of CD and 5-10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.

OriginalsprogEngelsk
TidsskriftJournal of Crohn's & colitis
Vol/bind15
Udgave nummer9
Sider (fra-til)1573-1587
Antal sider15
ISSN1873-9946
DOI
StatusUdgivet - 25 sep. 2021

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

ID: 62295732